[1]任芳芳,陈菲,付群,等.糖尿病视网膜病变患者疾病进展与房水细胞因子的相关性研究[J].眼科新进展,2024,44(6):464-469.[doi:10.13389/j.cnki.rao.2024.0090]
 REN Fangfang,CHEN Fei,FU Qun,et al.Correlation between the progression of diabetic retinopathy and cytokines in aqueous humor[J].Recent Advances in Ophthalmology,2024,44(6):464-469.[doi:10.13389/j.cnki.rao.2024.0090]
点击复制

糖尿病视网膜病变患者疾病进展与房水细胞因子的相关性研究/HTML
分享到:

《眼科新进展》[ISSN:1003-5141/CN:41-1105/R]

卷:
44卷
期数:
2024年6期
页码:
464-469
栏目:
应用研究
出版日期:
2024-06-03

文章信息/Info

Title:
Correlation between the progression of diabetic retinopathy and cytokines in aqueous humor
作者:
任芳芳陈菲付群张向东吴改萍杨邵晴宋影慧李洋来晶晶余涵
453003 河南省新乡市,新乡医学院第三附属医院眼科(任芳芳,付群,张向东,吴改萍,杨邵晴,宋影慧,李洋,来晶晶,余涵);510060 广东省广州市,中山大学中山眼科中心(陈菲)
Author(s):
REN Fangfang1CHEN Fei2FU Qun1ZHANG Xiangdong1WU Gaiping1YANG Shaoqing1SONG Yinghui1LI Yang1LAI Jingjing1YU Han1
1.Department of Ophthalmology,the Third Affiliated Hospital of Xinxiang Medical university,Xinxiang 453003,Henan Province,China
2.ZhongShan Ophthalmic Center,Sun Yat-Sen University,Guangzhou 510060,Guangdong Province,China
关键词:
糖尿病性视网膜病变细胞因子房水Luminex液相芯片
Keywords:
diabetic retinopathy cytokines aqueous humor Luminex assay
分类号:
R774.1
DOI:
10.13389/j.cnki.rao.2024.0090
文献标志码:
A
摘要:
目的 探讨糖尿病性视网膜病变(DR)患者行抗血管内皮生长因子(VEGF)治疗疗效与房水中细胞因子的相关性。
方法 纳入2023年7月至2023年12月在新乡医学院第三附属医院眼科行抗VEGF药物治疗的50例56眼DR患者,将患者分为糖尿病性黄斑水肿(DME)组(30例36眼)和增生型DR(PDR)组(20例20眼)。DME组患者每月玻璃体内注射阿柏西普眼内注射溶液1次,连续3次,每次注射前抽取房水;PDR组在行玻璃体切割术前1周玻璃体内注射阿柏西普眼内注射溶液1次,在注射前抽取房水,并在行玻璃体切割术时再次抽取房水。采用Luminex液相芯片检测每次抽取的房水内VEGF-A、胎盘生长因子(PLGF)、白细胞介素(IL)-1β、IL-23、IL-17A及肿瘤坏死因子α(TNF-α)的浓度。注射治疗前,所有患者均行最佳矫正视力(BCVA)和黄斑中心凹厚度(CMT)检测,分析注射治疗前各细胞因子浓度与DR患者BCVA及CMT的相关性。
结果 DME组患者注射治疗前后比较,房水中VEGF-A、PLGF及IL-23浓度均降低,差异均有统计学意义(均为P<0.05),此外,患者CMT值降低,BCVA提高,差异均有统计学意义(均为P<0.05)。PDR患者注射治疗后,房水中VEGF、PLGF、IL-1β、IL-23、IL-17A和TNF-α浓度均较注射治疗前降低,差异均有统计学意义(均为P<0.05)。注射治疗前,DME组患者房水中VEGF-A、PLGF及IL-23水平均高于PDR组患者,差异均有统计学意义(均为P<0.05)。相关分析结果显示,注射治疗前,DME组患者中,VEGF与BCVA呈负相关(r=-0.767,P=0.004);VEGF与CMT呈正相关(r=0.662,P=0.019);VEGF与IL-23呈正相关(r=0.765,P=0.004)。PDR组患者注射治疗前各房水细胞因子之间均无相关性(均为P>0.05)。
结论 VEGF-A、PLGF、IL-23的浓度变化与DR的发生发展密切相关,抗VEGF治疗可使DME患者BCVA得到改善,CMT下降。房水中IL-23的表达水平可作为DR患者抗VEGF疗效的预测因子,为DR的早诊断、早治疗提供新的靶点。
Abstract:
Objective To investigate the relationship between the therapeutic effect of anti-vascular endothelial growth factor (VEGF) and cytokines in aqueous humor in patients with diabetic retinopathy (DR).
Methods From July 2023 to December 2023, 50 DR patients (56 eyes) who were treated with anti-VEGF drugs in the Department of Ophthalmology, the Third Affiliated Hospital of Xinxiang Medical University were included in this study. The patients were divided into the diabetic macular edema (DME) group (30 patients, 36 eyes) and the proliferative DR (PDR) group (20 patients, 20 eyes). Patients in the DME group received an intravitreal injection of aflibercept once a month for three consecutive times, with aqueous humor extracted before each injection. Patients in the PDR group received an intravitreal injection of aflibercept one week before vitrectomy, with aqueous humor extracted before injection and during vitrectomy, respectively. The concentrations of vascular endothelial growth factor A (VEGF-A), placental growth factor (PLGF), interleukin (IL)-1β, IL-23, IL-17A, and tumor necrosis factor-α (TNF-α) in the aqueous humor were detected using the Luminex assay. Before injection therapy, all patients underwent best corrected visual acuity (BCVA) and central macular thickness (CMT) examinations, and their correlations with cytokine concentrations in DR patients before injection therapy were analyzed.
Results Compared to before injection therapy, the concentrations of VEGF-A, PLGF, and IL-23 in the aqueous humor of patients in the DME group decreased significantly after treatment (all P<0.05); additionally, the CMT decreased, and the BCVA increased (both P<0.05). After injection therapy, the concentrations of VEGF, PLGF, IL-1β, IL-23, IL-17A, and TNF-α in the aqueous humor of patients in the PDR group significantly decreased compared to before injection therapy (all P<0.05). Before injection therapy, the levels of VEGF-A, PLGF, and IL-23 in the aqueous humor of patients in the DME group were higher than those in the PDR group, and the differences were statistically significant (all P<0.05). The correlation analysis results showed that before injection therapy, VEGF was negatively correlated with BCVA (r=-0.767, P=0.004) and was positively correlated with CMT (r=0.662, P=0.019) and IL-23 (r=0.765, P=0.004) in the DME group. There was no correlation between the cytokines in the aqueous humor of patients in the PDR group before injection therapy (all P>0.05).
Conclusion Changes in the concentration of VEGF-A, PLGF, and IL-23 are closely related to the occurrence and development of DR. Anti-VEGF treatment can improve BCVA and decrease CMT in DME patients. The expression level of IL-23 in aqueous humor can serve as a predictive factor for the anti-VEGF efficacy in DR patients, providing new targets for early diagnosis and treatment of DR.

参考文献/References:

[1] 张建,关小东,方天敏,雷晓琴.房水细胞因子与糖尿病性黄斑水肿抗VEGF治疗疗效的相关性[J].中国医药导刊,2019,21(3):137-142.
ZHANG J,GUAN X D,FANG T M,LEI X Q.Correlation between levels of cytokines in aqueous humor and the efficacy of anti-VEGF therapy of diabetic macular edema patients[J].Chin J Med Guide,2019,21(3):137-142.
[2] 张敬法.炎症在糖尿病视网膜病变中的作用:发病机制及治疗策略[J].眼科新进展,2024,44(1):1-12.
ZHANG J F.Role of inflammation in diabetic retinopathy:pathogenesis and treatment strategies[J].Rec Adv Ophthalmol,2024,44(1):1-12.
[3] 宋蔚,赵帅,任百超,郅瑛.2型糖尿病患者白内障术后黄斑水肿与房水中TGF-β2、FGF及MCP-1的研究[J].临床眼科杂志,2016,24(5):385-387.
SONG W,ZHAO S,REN B C,ZHI Y.Relationships between macular edema and aqueous humor TGF-beta 2,FGF,MCP-1 levels in type 2 diabetes mellitus patients after cataract surgery[J].J Clin Ophthalmol,2016,24(5):385-387.
[4] 王富军,王文琦.《中国2型糖尿病防治指南(2020年版)》解读[J].河北医科大学学报,2021,24(12):1365-1371.
WANG F J,WANG W Q.Interpretation of Chinese Guidelines for the Prevention and Treatment of Type 2 diabetes (2020 Edition)[J].J Hebei Med Univ,2021,24(12):1365-1371.
[5] FUNATSU H,YAMASHITA H,NOMA H,MIMURA T,NAKAMURA S,SAKATA K,et al.Aqueous humor levels of cytokines are related to vitreous levels and progression of diabetic retinopathy in diabetic patients[J].Graefes Arch Clin Exp Ophthalmol,2005,243(1):3-8.
[6] MESQUITA J,CASTRO-DE-SOUSA J P,VAZ-PEREIRA S,NEVES A,PASSARINHA L A,TOMAZ C T.Evaluation of the growth factors VEGF-A and VEGF-B in the vitreous and serum of patients with macular and retinal vascular diseases[J].Growth Factors,2018,36(1-2):48-57.
[7] MATSUMOTO M,SUZUMA K,MAKI T,KINOSHITA H,TSUIKI E,FUJIKAWA A,et al.Succinate increases in the vitreous fluid of patients with active proliferative diabetic retinopathy[J].Am J Ophthalmol,2012,153(5):896-902.e1.
[8] BOULTON M,FOREMAN D,WILLIAMS G,MCLEOD D.VEGF localisation in diabetic retinopathy[J].Br J Ophthalmol,1998,82(5):561-568.
[9] EBOS J M L,LEE C R,BOGDANOVIC E,ALAMI J,VAN SLYKE P,FRANCIA G,et al.Vascular endothelial growth factor-mediated decrease in plasma soluble vascular endothelial growth factor receptor-2 levels as a surrogate biomarker for tumor growth[J].Cancer Res,2008,68(2):521-529.
[10] SUN Z,ZHOU H,LIN B,JIAO X,LUO Y,ZHANG F,et al.Efficacy and safety of intravitreal conbercept injections in macular edema secondary to retinal vein occlusion[J].Retina,2017,37(9):1723-1730.
[11] HORNIG C,BARLEON B,AHMAD S,VUORELA P,AHMED A,WEICH H A.Release and complex formation of soluble VEGFR-1 from endothelial cells and biological fluids[J].Lab Invest,2000,80(4):443-454.
[12] 张娇娇.IL-23在2型糖尿病视网膜病变患者血清及玻璃体中的表达[D].重庆:重庆医科大学,2015.
ZHANG J J.Expression of IL-23 in serum and vitreous of patients with type 2 diabetes retinopathy[D].Chongqing:Chongqing Medical University,2015.
[13] LIANG S C,TAN X Y,LUXENBERG D P,KARIM R,DUNUSSI-JOANNOPOULOS K,COLLINS M,et al.Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides[J].J Exp Med,2006,203(10):2271-2279.
[14] LITTMAN D R,RUDENSKY A Y.Th17 and regulatory T cells in mediating and restraining inflammation[J].Cell,2010,140(6):845-858.
[15] FUSS I J,BECKER C,YANG Z,GRODEN C,HORNUNG R L,HELLER F,et al.Both IL-12p70 and IL-23 are synthesized during active Crohn’s disease and are down-regulated by treatment with anti-IL-12 p40 monoclonal antibody[J].Inflamm Bowel Dis,2006,12(1):9-15.
[16] CASPI R R.A look at autoimmunity and inflammation in the eye[J].J Clin Invest,2010,120(9):3073-3083.
[17] CUA D J,SHERLOCK J,CHEN Y,MURPHY C A,JOYCE B,SEYMOUR B,et al.Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain[J].Nature,2003,421(6924):744-748.
[18] TANG C,CHEN S,QIAN H,HUANG W.Interleukin-23:as a drug target for autoimmune inflammatory diseases[J].Immunology,2012,135(2):112-124.
[19] CAI Y,TAN W,SHEN X,ZHU Y,GAO Y,SUI A,et al.Neutralization of IL-23 depresses experimental ocular neovascularization[J].Exp Eye Res,2016,146:242-251.
[20] 彭文怡,张明媚,易湘龙.伴黄斑水肿的非增殖期糖尿病视网膜病变患者房水、血清炎症介质水平变化[J].山东医药,2023,63(30):80-83.
PENG W Y,ZHANG M M,YI X L.Changes of aqueous humor and serum inflammatory mediators in non proliferative diabetes retinopathy patients with macular edema[J].Shandong Med J,2023,63(30):80-83.
[21] NOMA H,FUNATSU H,YAMASAKI M,TSUKAMOTO H,MIMURA T,SONE T,et al.Aqueous humour levels of cytokines are correlated to vitreous levels and severity of macular oedema in branch retinal vein occlusion[J].Eye,2008,22(1):42-48.
[22] JUNG S H,KIM K A,SOHN S W,YANG S J.Association of aqueous humor cytokines with the development of retinal ischemia and recurrent macular edema in retinal vein occlusion[J].Invest Ophthalmol Vis Sci,2014,55(4):2290-2296.
[23] LOPEZ-CASTEJON G,BROUGH D.Understanding the mechanism of IL-1β secretion[J].Cytokine Growth Factor Rev,2011,22(4):189-195.
[24] BERRY S P D,DOSSOU C,KASHIF A,SHARIFINEJAD N,AZIZI G,HAMEDIFAR H,et al.The role of IL-17 and anti-IL-17 agents in the immunopathogenesis and management of autoimmune and inflammatory diseases[J].Int Immunopharmacol,2022,102:108402.
[25] 叶国娟,金国玺,裴晓艳,李晓丽,毕娅欣.2型糖尿病患者血清B细胞激活因子、IL-17表达水平及其临床意义[J].牡丹江医学院学报,2020,41(2):94-97.
YE G J,JIN G X,PEI X Y,LI X L,BI Y X.Expression levels of serum B-cell activating factor and IL-17 in patients with type 2 diabetes mellitus and their clinical significance[J].J Mudanjiang Med Univ,2020,41(2):94-97.
[26] AVELEIRA C A,LIN C M,ABCOUWER S F,AMBRSIO A F,ANTONETTI D A.TNF-α signals through PKCζ/NF-κB to alter the tight junction complex and increase retinal endothelial cell permeability[J].Diabetes,2010,59(11):2872-2882.
[27] DOGANAY S,EVEREKLIOGLU C,ER H,TRKZ Y,SEVIN A,MEHMET N,et al.Comparison of serum NO,TNF-alpha,IL-1beta,sIL-2R,IL-6 and IL-8 levels with grades of retinopathy in patients with diabetes mellitus[J].Eye,2002,16(2):163-170.
[28] 朱洪丽.VEGF在PDR中的表达及作用的研究[J].国际眼科杂志,2014,14(12):2223-2225.
ZHU H L.Lnvestigation of correlations between vascular endothelial growth factor and proliferative diabetic retinopathy[J].Int Eye Sci,2014,14(12):2223-2225.

相似文献/References:

[1]李雪 刁玉梅 李兵.IL-12及 Th1/Th2细胞因子在 IL-10修饰的树突状细胞诱导大鼠角膜移植免疫耐受中的作用[J].眼科新进展,2012,32(5):000.
[2]张 洁 孟小妹 张亦农.重度非增殖性与增殖性糖尿病性视网膜病变多焦视网膜电图一阶函数核的特征分析[J].眼科新进展,2008,28(9):000.
[3]吴岩 于靖.增生性玻璃体视网膜病变相关蛋白研究进展[J].眼科新进展,2012,32(1):000.
[4]詹文捷 梁丽娜 唐由之.骨髓来源细胞参与脉络膜新生血管形成的研究进展[J].眼科新进展,2012,32(1):000.
[5]孙爽 罗予 张金嵩 杜楠楠.外伤性眼内炎兔房水中细胞因子的表达[J].眼科新进展,2012,32(8):000.
[6]刘旭辉 张孝生 李中秋 王婧 张晓龙 卢弘.Toll样受体4对HLA-B27相关前葡萄膜炎患者外周血单个核细胞分泌细胞因子的影响[J].眼科新进展,2012,32(9):000.
[7]兰文 陆燕 王春红 胡钦瑞 黄振平.糖尿病视网膜病变炎症的研究新进展[J].眼科新进展,2013,33(2):000.
[8]刘苹 康刚劲.细胞因子在后发性白内障发病机制中的研究进展[J].眼科新进展,2013,33(3):000.
[9]张敏,储三军,曾繁星,等. Bevacizumab对视网膜色素上皮细胞纤维化相关因子表达的影响[J].眼科新进展,2014,34(4):318.[doi:10.13389/j.cnki.rao.2014.0086]
[10]陈娟,吕红彬. 抗VEGF药物在糖尿病性视网膜病变治疗中的应用[J].眼科新进展,2014,34(4):397.[doi:10.13389/j.cnki.rao.2014.0110]

备注/Memo

备注/Memo:
新乡市科技攻关计划项目(编号:GG2021040)
更新日期/Last Update: 2024-06-05